Karbamazepine, (CBZ) is a well-known antiepileptic drug which significantly changes the lipid profile, but there are no published data about the possible interaction between Lamotrigine (LTG) and the lipid metabolism. Therefore, this study was conducted to reveal the hypothetically different impact of antiepileptic therapy on the lipid metabolism in patients taking CBZ and in those on therapy with LTG. The lipid profile was analysed in two groups of randomly selected autopatients treated for localization related epilepsy, taking CBZ (N=16) or LTG (N=16) as monotherapy. The inclusion therapies were age (18-65 years) and duration of the therapy (>3 months). The patients taking concomitant medications, which could change sera lipids was excluded. There were no significant differences between the groups regarding gender or age. Statistical differences were found for total cholesterol (CBZ group: 5.58 ± ; 1.26 mmol/L, LTG group: 4.76 ± ; 1.04 mmol/L ; P=0.048) and for LDL cholesterol (CBZ group: 3.48 ± ; 1.08 mmol/L, LTG group: 2.84 ± ; 0.86 mmol/L, P=0.027). There were no significant differences between to groups concerning any other measured parameters: total HDL cholesterol, HDL-2 cholesterol, HDL-3 cholesterol, VLDL cholesterol, tryglicerides, apolipoprotein A-1 and apolipoprotein B. The obtained results suggests the possibility that monotherapy with LTG compared to CBZ monotherapy might be associated with a more favourable lipid profile. This might be explained by different biotransformation pathways of these drugs.

Clinical medical sciences,Pharmacology